Evidence map›Paper›PMID 42696583›Full record

ArticleScience advances2026

Supramolecular immunomodulatory hydrogelator potentiates CAR-T therapy with long-lasting endogenous immunity toward solid tumor eradication.

Chenwei Jiang, Minglu Tang, Mingmei Guo, Qi Shang, Qi Chen, Xiaoran An, Junjie Xie, Kangqi Zheng, Bing Feng, Feihu Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chenwei JiangSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.ORCID 0009-0006-8682-2380
Minglu TangSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.ORCID 0009-0005-6341-1872
Mingmei GuoSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
Qi ShangSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.ORCID 0000-0002-4737-0063
Qi ChenDepartment of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.ORCID 0009-0009-4286-0029
Xiaoran AnSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
Junjie XieSchool of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.ORCID 0009-0003-4487-2791
Kangqi ZhengSchool of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China.
Bing FengHangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou 310000, China.ORCID 0000-0002-6108-2017
Feihu WangSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.ORCID 0000-0002-0358-967X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The success of chimeric antigen receptor (CAR)-T cell therapy in hematologic malignancies has not been translated to solid tumors, primarily due to inadequate T cell infiltration and an immunosuppressive tumor microenvironment that drives T cell exhaustion. To address these challenges, we developed a tailored immunomodulatory drug-drug conjugate-based hydrogelator for the localized delivery of CAR-T cells targeting solid tumors. This hydrogel forms an in situ scaffold that serves as a sustained-release reservoir, enabling continuous co-delivery of CAR-T cells along with immunomodulatory agents-NLG919 (an IDO-1 inhibitor) and

Indexed as

HydrogelsImmunomodulating AgentsImmunotherapy, AdoptiveNeoplasmsReceptors, Chimeric AntigenAnimalsCell Line, TumorFemaleHumansMiceT-LymphocytesTumor MicroenvironmentHydrogelsImmunomodulating AgentsReceptors, Chimeric Antigen

Identifiers

PMID42696583
PMCPMC13544216

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.